EZH2 and neoplasm: To verify whether dysfunctional T cells are enriched in tumor-specificities at this early time point, we took advantage of MHC dextramers to identify tumor-specific (WT1, PRAME, or EZH2) and control viral-specific (cytomegalovirus-CMV) CD8+ T cells from patients.